Over 8,000 severe brain injuries have been recorded during Iraq and Afghanistan warfare. PTSD affects about 7.7 million American adults in a given year. We are seeking to develop a therapy that will reduce or remove ailments, better incorporate these warriors into our society, decrease lost duty time, and mitigate the life-long disability and rehabilitation costs associated with these post-injury conditions.
The vastness of destruction entailed in warfare places an enormous stress on the mental fortitude of our warriors. Whether through direct trauma to the head or from the relentless strain of peril and vision of devastation, our warriors incur heightened rates of mental debilitations.
The current standard of care for TBI is based on management of symptoms and there remains no U.S. Food and Drug Administration (FDA) approved drug therapy for the treatment of TBI. We are seeking to develop a therapy that will reduce or remove ailments, better incorporate these warriors into our society, decrease lost duty time, and mitigate the life-long disability and rehabilitation costs associated with these post-injury conditions.
MTEC funds active, ongoing, scientifically validated and clinically relevant projects. Our new medical technologies improve the lives of our warriors and all the people they protect but the long-term impact will help to accelerate them toward use within the general population.
